PCK1 and neoplasm: Consequently, this treatment abrogates PCK1‐mediated phosphorylation of Insig1 at S207 and Insig2 at S151, reduces the nuclear accumulation of SREBP1, and decreases SREBP1 activity‐dependent expression of lipid synthesis genes, lipid accumulation, and tumor cell proliferation.